摘要
MicroRNA(miRNAs)是小的非编码RNA分子,其精密调节基因的表达。 miRNAs涉及生理细胞过程,然而当它们放松管制时已经与一些病状包括癌症相关联。在人类乳腺癌中,miRNAs表达水平的差异已经被识别同那些在正常乳腺组织相比较。此外,一些MiRNAs与病理表型、癌症亚型和在乳腺癌治疗的反应相关。对治疗的抵抗是在患者管理中越来越多地出现的问题,并且miRNAs正成为新的治疗靶向和潜在的治疗预测生物标志物。本文综述了在乳腺癌中miRNAs当前状况的概述,侧重于他们在耐药的参与性和循环miRNAs。通过miRNAs调控治疗耐药机制,如受体的调控、对药物代谢酶的修饰、细胞周期控制或促凋亡蛋白,组蛋白活性的改变和除了其他外的DNA修复机制的调控,这些是乳腺癌的临床亚型所讨论的。此外,在此文中,我们总结了近期已建立了的知识关于miRNA检测在外周体液中作为一个合适的生物标记。我们总结了miRNA检测在液体活检和其对乳腺癌的诊断和监测的影响。这种新一代的癌症生物标志物可能会对在患者管理上有一个显著的改善。
关键词: AngiomiRs;乳腺癌;循环microRNAs;microRNA;oncomiRs;主链;肿瘤抑制基因
图形摘要
Current Drug Targets
Title:MicroRNAs in Breast Cancer: One More Turn in Regulation
Volume: 17 Issue: 9
Author(s): Pilar E. Asensio, Eduardo T. Martin, Begona P. Merlo, Estefanía E. Armas, Ana L. Hernández
Affiliation:
关键词: AngiomiRs;乳腺癌;循环microRNAs;microRNA;oncomiRs;主链;肿瘤抑制基因
摘要: MicroRNAs (miRNAs) are small non-coding RNA molecules that critically regulate the expression of genes. MiRNAs are involved in physiological cellular processes; however, their deregulation has been associated with several pathologies, including cancer. In human breast cancer, differently expressed levels of miRNAs have been identified from those in normal breast tissues. Moreover, several miRNAs have been correlated with pathological phenotype, cancer subtype and therapy response in breast cancer. The resistance to therapy is increasingly a problem in patient management, and miRNAs are emerging as novel therapeutic targets and potential predictive biomarkers for treatment. This review provides an overview of the current situation of miRNAs in breast cancer, focusing on their involvement in resistance and the circulating miRNA. The mechanisms of therapeutic resistance regulated by miRNAs, such as the regulation of receptors, the modification of enzymes of drug metabolism, the inhibition of cell cycle control or pro-apoptotic proteins, the alteration of histone activity and the regulation of DNA repair machinery among others, are discussed for breast cancer clinical subtypes. Additionally, in this review, we summarize the recent knowledge that has established miRNA detection in peripheral body fluids as a suitable biomarker. We review the detection of miRNA in liquid biopsies and its implications for the diagnosis and monitoring of breast cancer. This new generation of cancer biomarkers may lead to a significant improvement in patient management.
Export Options
About this article
Cite this article as:
Pilar E. Asensio, Eduardo T. Martin, Begona P. Merlo, Estefanía E. Armas, Ana L. Hernández , MicroRNAs in Breast Cancer: One More Turn in Regulation, Current Drug Targets 2016; 17 (9) . https://dx.doi.org/10.2174/1389450116666150213114103
DOI https://dx.doi.org/10.2174/1389450116666150213114103 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Reduced Folate Carrier Gene and Transcript Variants: Functional, Physiologic, and Pharmacologic Consequences
Current Pharmacogenomics Nanostructured Cubosomes as a Platform for Oral Drug Delivery
Current Pharmaceutical Biotechnology The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer
Anti-Cancer Agents in Medicinal Chemistry Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Plumbagin: A Potential Anti-cancer Compound
Mini-Reviews in Medicinal Chemistry Polymeric Nanomicelles of Soluplus® as a Strategy for Enhancing the Solubility, Bioavailability and Efficacy of Poorly Soluble Active Compounds
Current Nanomedicine Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Nanoparticle-Delivered Quercetin for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Should the Status of the Pathway Mediated by BRCA1 and BRCA2 be Evaluated Before Selecting Cancer Chemotherapy Drugs?
Current Pharmacogenomics Imiquimod 5% Cream Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Anti-Inflammatory Actions of the Heme Oxygenase-1 Pathway
Current Pharmaceutical Design Down-Regulation of DDR1 Induces Apoptosis and Inhibits EMT through Phosphorylation of Pyk2/MKK7 in DU-145 and Lncap-FGC Prostate Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?
Current Medicinal Chemistry Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Role of Rap2 and its Downstream Effectors in Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry The Role of Estrogen and Estrogen Receptors in Chemoresistance
Current Medicinal Chemistry